Cash Flow Statement
Growth Metrics

Anika Therapeutics (ANIK) Receivables - Net (2016 - 2026)

Anika Therapeutics has reported Receivables - Net over the past 17 years, most recently at $26.9 million for Q1 2026.

  • Quarterly Receivables - Net rose 22.16% to $26.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $26.9 million through Mar 2026, up 22.16% year-over-year, with the annual reading at $23.7 million for FY2025, 0.41% changed from the prior year.
  • Receivables - Net was $26.9 million for Q1 2026 at Anika Therapeutics, up from $23.7 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $38.4 million in Q2 2023 and troughed at $22.0 million in Q1 2025.
  • The 5-year median for Receivables - Net is $27.6 million (2024), against an average of $29.1 million.
  • Year-over-year, Receivables - Net crashed 34.82% in 2025 and then increased 22.16% in 2026.
  • A 5-year view of Receivables - Net shows it stood at $34.6 million in 2022, then dropped by 23.87% to $26.4 million in 2023, then fell by 10.49% to $23.6 million in 2024, then increased by 0.41% to $23.7 million in 2025, then grew by 13.38% to $26.9 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Receivables - Net are $26.9 million (Q1 2026), $23.7 million (Q4 2025), and $23.1 million (Q3 2025).